spacer
home > ebr > winter 2018 > discovery decisions
PUBLICATIONS
European Biopharmaceutical Review

Discovery Decisions

The discovery of new drugs is driven by data. The data generated on compounds’ activities – in combination with absorption, distribution, metabolism and elimination (ADME), physicochemical and safety properties – enable selection of compounds for progression to further study. These data are also used to identify relationships between the structures of compounds and their observed activities and properties – structure-activity relationships (SAR) – guiding the design of improved compounds against a project’s objectives. In accessing these data, time is of the essence; selecting compounds based on incomplete or out-of-date information or designing new compounds without the latest results can lead to wasted time and effort through redundant experiments being performed and poor compounds being synthesised.

Managing Data

Large pharma companies use sophisticated laboratory information management platforms to capture information and store the results in large databases or data ‘warehouses’. Entire departments are devoted to ensuring the coherence of these data because of their value to the company. Smaller organisations often do not have this luxury, and, in the worst cases, may have data from a variety of sources stored in individual files, in different locations and maintained by a range of scientists (often for their personal use). In the latter case, how much value is lost when data, often generated at high cost, are not available to the decision-makers in a project?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Matthew Segall has an MSc in computation from the University of Oxford, UK, and a PhD in theoretical physics from the University of Cambridge, UK. At Camitro, ArQule and Inpharmatica, Matt led a team developing predictive ADME models and intuitive decision-support tools for drug discovery. In 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director of BioFocus DPI’s ADMET division and, in 2009, founded Optibrium, which develops software for small molecule design, optimisation and data analysis. 

Dr Chris Leeding has a PhD in chemistry from King’s College, London, UK and his career has focused on scientific software development. Chris has worked on the development of StarDrop since 2006, most recently as Optibrium’s Director of Product Development, and taken a lead role in integrating StarDrop with customers’ database and informatics infrastructure.

spacer
Dr Matthew Segall
spacer
spacer
spacer
Dr Chris Leeding
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast

6-8 June 2018, Crowne Plaza, San Diego, CA, USA

SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA, on the 7th and 8th of June 2018. Delivering updates and promoting discussion on key challenges and developments within the pharmaceutical microbiology industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement